Compound Evidence File
#EC-2026-0007
Ostarine (MK-2866)
Filed under Oral Tablets. The bureau holds 115 laboratory returns for this compound from 45 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
45 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 19 Jan 2026 | 3 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Apr 2026 | 2 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 12 Dec 2025 | 14 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Apr 2026 | 11 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Jan 2026 | 9 Jun 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Feb 2026 | 19 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Nov 2025 | 11 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 17 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 9.9 | 12 Mar 2026 | 2 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Dec 2025 | 24 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 1 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Nov 2025 | 21 Mar 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 16 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 9.6 | 9.6 | 9.6 | 28 Mar 2025 | 28 Mar 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 9.2 | 7.8 | 9.8 | 24 May 2026 | 24 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 2 | 9.1 | 8.4 | 9.7 | 3 Jul 2025 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.9 | 8.7 | 9.1 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.8 | 7.4 | 9.8 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.4 | 7.0 | 9.4 | 23 May 2026 | 23 May 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 8.4 | 8.4 | 8.4 | 13 Jun 2025 | 13 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.3 | 7.1 | 8.9 | 21 May 2026 | 21 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 7.9 | 7.9 | 7.9 | 3 Jun 2025 | 3 Jun 2025 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 7.7 | 7.7 | 7.7 | 6 May 2025 | 6 May 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 7.3 | 7.2 | 7.5 | 8 Jul 2025 | 20 May 2026 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 7.3 | 7.3 | 7.3 | 6 May 2025 | 6 May 2025 |
| Mai PeptideCASE #VI-2026-0769 | X | 4 | 7.2 | 6.4 | 8.6 | 20 Jun 2025 | 23 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 9 | 7.0 | 4.7 | 8.6 | 25 Apr 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 7.0 | 7.0 | 7.0 | 2 Jul 2025 | 2 Jul 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.5 | 6.5 | 6.6 | 3 Jul 2025 | 24 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 6.5 | 5.4 | 7.5 | 17 Dec 2024 | 24 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 1 | 6.4 | 6.4 | 6.4 | 9 Jun 2025 | 9 Jun 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.3 | 6.3 | 6.3 | 9 Jun 2025 | 9 Jun 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 6.2 | 6.2 | 6.2 | 20 Jun 2025 | 20 Jun 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 6.2 | 6.2 | 6.2 | 3 Jul 2025 | 3 Jul 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 6.1 | 6.1 | 6.1 | 13 Jun 2025 | 13 Jun 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 5.6 | 5.6 | 5.6 | 9 Jun 2025 | 9 Jun 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 5.0 | 5.0 | 5.0 | 14 Jan 2025 | 14 Jan 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 4.9 | 4.9 | 4.9 | 9 Jun 2025 | 9 Jun 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 4.1 | 4.1 | 4.1 | 24 Apr 2025 | 24 Apr 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 3.5 | 3.5 | 3.5 | 17 Dec 2024 | 17 Dec 2024 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.6 | 0.6 | 0.6 | 16 Mar 2025 | 16 Mar 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Ostarine (MK-2866) alone.